{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:02:24Z","timestamp":1790352144427,"version":"4.1.0"},"publisher-location":"Berlin, Heidelberg","reference-count":64,"publisher":"Springer Berlin Heidelberg","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/164_2026_836","type":"book-chapter","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:22:33Z","timestamp":1790349753000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recent Advances in the Application and Development of Coordinated Radiopharmaceuticals"],"prefix":"10.1007","author":[{"given":"Yinghuai","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianghong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narayan S.","family":"Hosmane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,26]]},"reference":[{"key":"836_CR1","doi-asserted-by":"crossref","unstructured":"Azam A, Kurbegovic S, Carlsen EA et al. Prospective phase II trial of [68Ga]Ga-NOTA-AE105 uPAR-PET\/MRI in patients with primary gliomas: Prognostic value and Implications for uPAR-targeted Radionuclide Therapy. (2024) EJNMMI Res 14:100","DOI":"10.1186\/s13550-024-01164-9"},{"key":"836_CR2","doi-asserted-by":"crossref","unstructured":"Babeker H, Njotu FN, Ketchemen JP et al.\u00a0225Ac\/89Zr-Labeled N4MU01 Radioimmunoconjugates as Theranostics Against Nectin-4-Positive Triple-Negative Breast Cancer. (2025) J Nucl Med 66:592\u2013598","DOI":"10.2967\/jnumed.124.268387"},{"key":"836_CR3","doi-asserted-by":"crossref","unstructured":"Ballal S, Yadav MP, Bal C et al. Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety. (2020) Eur J Nucl Med Mol Imaging 47:934\u2013946","DOI":"10.1007\/s00259-019-04567-2"},{"key":"836_CR4","doi-asserted-by":"crossref","unstructured":"Ballal S, Yadav MP, Satapathy S et al.\u00a0Long-term survival outcomes of salvage [225Ac]Ac-PSMA-617 targeted alpha therapy in patients with PSMA-expressing end-stage metastatic castration-resistant prostate cancer: a real-world study.\u00a0(2023) Eur J Nucl Med Mol Imaging 50:3777\u20133789","DOI":"10.1007\/s00259-023-06340-y"},{"key":"836_CR5","doi-asserted-by":"crossref","unstructured":"Beyer GJ, Miederer M, Vranjes-Duri\u0107 S et al.\u00a0Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using 149Tb-rituximab. (2004) Eur J Nucl Med Mol Imaging 31:547\u2013554","DOI":"10.1007\/s00259-003-1413-9"},{"key":"836_CR6","doi-asserted-by":"crossref","unstructured":"B\u00f6hnke N, Indrevoll B, Hammer S et al.\u00a0Mono- and multimeric PSMA-targeting small molecule-thorium-227 conjugates for optimized efficacy and biodistribution in preclinical models. (2024) Eur J Nucl Med Mol Imaging 51:669\u2013680","DOI":"10.1007\/s00259-023-06474-z"},{"key":"836_CR7","doi-asserted-by":"crossref","unstructured":"Borthakur R, Chandrasekhar V.\u00a0Boron-heteroelement (B\u2013E; E = Al, C, Si, Ge, N, P, As, Bi, O, S, Se, Te) multiply bonded compounds: Recent advances. (2021) Coord Chem Rev 429:213647","DOI":"10.1016\/j.ccr.2020.213647"},{"key":"836_CR8","doi-asserted-by":"crossref","unstructured":"Brenner AJ, Patel T, Bao A et al.\u00a0Convection enhanced delivery of Rhenium (186Re) Obisbemeda (186RNL) in recurrent glioma: a multicenter, single arm, phase 1 clinical trial. (2025) Nat Commun 16:2079","DOI":"10.1038\/s41467-025-57263-1"},{"key":"836_CR9","unstructured":"Capello A, Krenning EP, Breeman WA et al.\u00a0Peptide receptor radionuclide therapy in vitro using [111In-DTPA0]octreotide. (2003) J Nucl Med 44:98\u2013104"},{"key":"836_CR10","doi-asserted-by":"crossref","unstructured":"Chan HS, de Blois E, Morgenstern A et al.\u00a0In Vitro comparison of 213Bi- and 177Lu-radiation for peptide receptor radionuclide therapy. (2017) PLoS One 12:e0181473","DOI":"10.1371\/journal.pone.0181473"},{"key":"836_CR11","doi-asserted-by":"crossref","unstructured":"Cheson BD.\u00a0The Role of Radioimmunotherapy with Yttrium- 90 Ibritumomab Tiuxetan in the Treatment of Non-Hodgkin Lymphoma. (2005) BioDrugs 19:309\u2013322","DOI":"10.2165\/00063030-200519050-00004"},{"key":"836_CR12","doi-asserted-by":"crossref","unstructured":"Cho HJ, Huynh TT, Rogers BE et al.\u00a0Design of a multivalent bifunctional chelator for diagnostic 64Cu PET imaging in Alzheimer's disease. (2020) Proc Natl Acad Sci USA 117:30928-30933.","DOI":"10.1073\/pnas.2014058117"},{"key":"836_CR13","doi-asserted-by":"crossref","unstructured":"Chopra S, Shukla J, Purohit P et al.\u00a0Exploring currently available fibroblast activation protein targeting molecules in adrenocortical carcinoma: Navigating theranostic pathways. (2025) Eur J Nucl Med Mol Imaging 52:3618\u20133631","DOI":"10.1007\/s00259-025-07203-4"},{"key":"836_CR14","doi-asserted-by":"crossref","unstructured":"Deben C, Boullosa LF, Fortes FR et al.\u00a0Auranofin repurposing for lung and pancreatic cancer: low CA12 expression as a marker of sensitivity in patient-derived organoids, with potentiated efficacy by AKT inhibition. (2024) J Exp Clin Cancer Res 43:88","DOI":"10.1186\/s13046-024-03012-z"},{"key":"836_CR15","doi-asserted-by":"crossref","unstructured":"Delpassand ES, Tworowska I, Esfandiari R et al.\u00a0Targeted \u03b1-Emitter Therapy with 212Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial. (2022) J Nucl Med 63:1326\u20131333","DOI":"10.2967\/jnumed.121.263230"},{"key":"836_CR16","doi-asserted-by":"crossref","unstructured":"Domnanich KA, M\u00fcller C, Farkas R et al.\u00a044Sc for labeling of DOTA- and NODAGA-functionalized peptides: preclinical in vitro and in vivo investigations. (2016) EJNMMI Radiopharm Chem 1:8","DOI":"10.1186\/s41181-016-0013-5"},{"key":"836_CR17","doi-asserted-by":"crossref","unstructured":"O'Donoghue JA, Wheldon TE.\u00a0Targeted radiotherapy using Auger electron emitters. (1996) Phys Med Biol 41:1973\u20131992","DOI":"10.1088\/0031-9155\/41\/10\/009"},{"key":"836_CR18","doi-asserted-by":"crossref","unstructured":"Ells Z, Grogan TR, Czernin J et al.\u00a0Dosimetry of [177Lu]Lu-PSMA-Targeted Radiopharmaceutical Therapies in Patients with Prostate Cancer: A Comparative Systematic Review and Metaanalysis. (2024) J Nucl Med 65:1264\u20131271","DOI":"10.2967\/jnumed.124.267452"},{"key":"836_CR19","doi-asserted-by":"crossref","unstructured":"Fonseca AI, Sereno J, Almeida S et al.\u00a0Unveiling the potential of copper-61 vs. gallium-68 for SSTR PET imaging. (2025) Eur J Nucl Med Mol Imaging 52:2671\u20132684","DOI":"10.1007\/s00259-025-07116-2"},{"key":"836_CR20","doi-asserted-by":"crossref","unstructured":"Fragoso P, Costa K, Shi K, et al.\u00a0Surgical radioguidance with beta-emitting radionuclides; challenges and possibilities: A position paper by the EANM. (2024) Eur J Nucl Med Mol Imaging 51:2903\u20132921","DOI":"10.1007\/s00259-023-06560-2"},{"key":"836_CR21","doi-asserted-by":"crossref","unstructured":"Fu H, Huang J, Sun L et al.\u00a0FAP-Targeted Radionuclide Therapy of Advanced Radioiodine-Refractory Differentiated Thyroid Cancer With Multiple Cycles of 177 Lu-FAPI-46. (2022) Clin Nucl Med 47:906\u2013907","DOI":"10.1097\/RLU.0000000000004260"},{"key":"836_CR22","doi-asserted-by":"crossref","unstructured":"Fu H, He H, Wang Y et al.\u00a0Preliminary evaluation of a novel PSMA-targeting radiopharmaceutical [68Ga]Ga\/[177Lu]Lu-NYM032 for theranostic use in prostate cancer. (2025) Eur J Nucl Med Mol Imaging 52:1671\u20131684","DOI":"10.1007\/s00259-024-07046-5"},{"key":"836_CR23","doi-asserted-by":"crossref","unstructured":"Genz J, Berton C, Kichou S et al.\u00a0Photoradiolabeling of onartuzumab with 99mTc and 188Re-tricarbonyl for radiotheranostics of gastric cancer. (2025) Chem Sci 16:6219\u20136230","DOI":"10.1039\/D4SC08089K"},{"key":"836_CR24","doi-asserted-by":"crossref","unstructured":"Gill MR, Falzone N, Du Y, Vallis KA.\u00a0Targeted radionuclide therapy in combined-modality regimens. (2017) Lancet Oncol 18:414\u2013423","DOI":"10.1016\/S1470-2045(17)30379-0"},{"key":"836_CR25","doi-asserted-by":"crossref","unstructured":"Habouzit V, Casteillo F, Boutallaka H et al.\u00a0Macrophagic Reaction to Sodium Polystyrene Sulfonate Crystals Mimicking Peritoneal Carcinomatosis on 18 F-FDG PET\/CT in Rectal Cancer. (2025) Clin Nucl Med 50:933\u2013935","DOI":"10.1097\/RLU.0000000000005917"},{"key":"836_CR26","doi-asserted-by":"crossref","unstructured":"Helisch A, Kratochwil C, Kleist C et al.\u00a0Feasibility, Tolerability, and Preliminary Clinical Response of Fractionated Radiopharmaceutical Therapy with 213Bi-FAPI-46: Pilot Experience in Patients with End-Stage, Progressive Metastatic Tumors. (2024) J Nucl Med 65:1917\u20131922","DOI":"10.2967\/jnumed.124.268386"},{"key":"836_CR27","doi-asserted-by":"crossref","unstructured":"Hernandez R, Valdovinos HF, Yang Y et al.\u00a0(44)Sc: an attractive isotope for peptide-based PET imaging. (2014) Mol Pharm 11:2954\u20132961","DOI":"10.1021\/mp500343j"},{"key":"836_CR28","doi-asserted-by":"crossref","unstructured":"Hohenberger P, Rathmann N, B\u00fcsing K et al.\u00a0Selective internal radiation with Y-90 resin microspheres (SIRT) for liver metastases of gastro-intestinal stromal tumors (GIST) resistant to tyrosine kinase inhibitor (TKI) therapy. (2025) Br J Cancer 132:716\u2013724","DOI":"10.1038\/s41416-025-02952-3"},{"key":"836_CR29","doi-asserted-by":"crossref","unstructured":"Hosmane NS, Maguire JA, Zhu Y, Takagaki M (eds) (2012) boron and gadolinium neutron capture therapy for cancer treatment. World Scientific Pub Co Inc. pp 20-270.","DOI":"10.1142\/8056"},{"key":"836_CR30","doi-asserted-by":"crossref","unstructured":"Imhof A, Brunner P, Marincek N et al.\u00a0Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. (2011) J Clin Oncol 29:2416\u20132423","DOI":"10.1200\/JCO.2010.33.7873"},{"key":"836_CR31","doi-asserted-by":"crossref","unstructured":"Ioannidis I, Lefkaritis G, Georgiades SN et al.\u00a0Towards Clinical Development of Scandium Radioisotope Complexes for Use in Nuclear Medicine: Encouraging Prospects with the Chelator 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic Acid (DOTA) and Its Analogues. (2024) Int J Mol Sci 25:5954","DOI":"10.3390\/ijms25115954"},{"key":"836_CR32","doi-asserted-by":"crossref","unstructured":"Jia Y, Shi S, Jin C.\u00a0Advancing Neuro-oncology Diagnostics: A Prospective Evaluation of 68Ga-Pentixafor PET\/CT Imaging for CXCR4 Overexpression in High-grade Gliomas and Its Implications for Personalized Treatment. (2025) Acad Radiol 32:1773","DOI":"10.1016\/j.acra.2024.12.066"},{"key":"836_CR33","doi-asserted-by":"crossref","unstructured":"Kankanamalage P, Hoerres R, Ho KV et al.\u00a0p-NCS-Bn-NODAGA as a bifunctional chelator for radiolabeling with the 186Re\/99mTc-tricarbonyl core: Radiochemistry with model complexes and a GRPR-targeting peptide. (2022) Nucl Med Biol 108\u2013109:1\u20139","DOI":"10.1016\/j.nucmedbio.2022.01.004"},{"key":"836_CR34","doi-asserted-by":"crossref","unstructured":"Kim WK, An JM, Lim YJ et al.\u00a0Recent advances in metallodrug: Coordination-induced synergy between clinically approved drugs and metal ions. (2025) Mater Today Adv 25:100569","DOI":"10.1016\/j.mtadv.2025.100569"},{"key":"836_CR35","doi-asserted-by":"crossref","unstructured":"Kleynhans J, Ebenhan T, Cleeren F, Sathekge MM.\u00a0Can current preclinical strategies for radiopharmaceutical development meet the needs of targeted alpha therapy? (2024) Eur J Nucl Med Mol Imaging 51:1965\u20131980","DOI":"10.1007\/s00259-024-06719-5"},{"key":"836_CR36","doi-asserted-by":"crossref","unstructured":"Kratochwil C, Giesel FL, Bruchertseifer F et al.\u00a0\u00b2\u00b9\u00b3Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. (2014) Eur J Nucl Med Mol Imaging 41:2106\u20132119","DOI":"10.1007\/s00259-014-2857-9"},{"key":"836_CR37","doi-asserted-by":"crossref","unstructured":"Ku A, Facca VJ, Cai Z, Reilly RM.\u00a0Auger electrons for cancer therapy - a review. (2019) EJNMMI Radiopharm Chem 4:27","DOI":"10.1186\/s41181-019-0075-2"},{"key":"836_CR38","doi-asserted-by":"crossref","unstructured":"Labadie KP, Hamlin DK, Kenoyer A et al.\u00a0Glypican-3-Targeted 227Th \u03b1-Therapy Reduces Tumor Burden in an Orthotopic Xenograft Murine Model of Hepatocellular Carcinoma.(2022) J Nucl Med 63:1033\u20131038","DOI":"10.2967\/jnumed.121.262562"},{"key":"836_CR39","doi-asserted-by":"crossref","unstructured":"Laoruangroj C, Atherton PJ, Wiseman GA et al.\u00a0The asymptomatic follicular lymphoma (AFL) trial: single-agent rituximab immunotherapy versus 90Y-ibritumomab tiuxetan radioimmunotherapy (RIT) for patients with new, untreated follicular lymphoma. (2024) Leuk Lymphoma 65:333\u2013338","DOI":"10.1080\/10428194.2023.2295792"},{"key":"836_CR40","doi-asserted-by":"crossref","unstructured":"Lee I, Lim I, Byun BH et al.\u00a0A preliminary clinical trial to evaluate 64Cu-NOTA-Trastuzumab as a positron emission tomography imaging agent in patients with breast cancer. (2021) EJNMMI Res 11:8","DOI":"10.1186\/s13550-021-00746-1"},{"key":"836_CR41","doi-asserted-by":"crossref","unstructured":"Li RG, Stenberg VY, Larsen RH.\u00a0An Experimental Generator for Production of High-Purity 212Pb for Use in Radiopharmaceuticals. (2023) J Nucl Med 64:173\u2013176","DOI":"10.2967\/jnumed.122.264009"},{"key":"836_CR42","doi-asserted-by":"crossref","unstructured":"Liu T, Karlsen M, Karlberg AM, Redalen KR.\u00a0Hypoxia imaging and theranostic potential of [64Cu][Cu(ATSM)] and ionic Cu(II) salts: a review of current evidence and discussion of the retention mechanisms. (2020) EJNMMI Res 10:33","DOI":"10.1186\/s13550-020-00621-5"},{"key":"836_CR43","doi-asserted-by":"crossref","unstructured":"Liu Y, Watabe T, Kaneda-Nakashima K et al.\u00a0Fibroblast activation protein targeted therapy using [177Lu]FAPI-46 compared with [225Ac]FAPI-46 in a pancreatic cancer model. (2022) Eur J Nucl Med Mol Imaging 49:871\u2013880","DOI":"10.1007\/s00259-021-05554-2"},{"key":"836_CR44","doi-asserted-by":"crossref","unstructured":"Lorenzoni A, Capozza A, Artale S et al.\u00a0Impressive Response to Tandem Treatment With [90Y]DOTATOC and [177Lu]DOTATOC in Grade 3 Pancreatic Neuroendocrine Carcinoma. (2018) Clin Nucl Med 43:506\u2013508","DOI":"10.1097\/RLU.0000000000002116"},{"key":"836_CR45","unstructured":"Ma JQ, Zhang LH, Yang MJ et al.\u00a0Yttrium-90 selective internal radiation therapy on liver cancer: the past, the present, and the future. (2025) Chin J Clin Med 32:3\u20138"},{"key":"836_CR46","doi-asserted-by":"crossref","unstructured":"M\u00fcller C, Vermeulen C, K\u00f6ster U et al.\u00a0Alpha-PET with terbium-149: evidence and perspectives for radiotheragnostics. (2016) EJNMMI Radiopharm Chem 1:5","DOI":"10.1186\/s41181-016-0008-2"},{"key":"836_CR47","doi-asserted-by":"crossref","unstructured":"Nelson BJB, Wilson J, Andersson JD, Wuest F.\u00a0High yield cyclotron production of a novel 133\/135La theranostic pair for nuclear medicine. (2020) Sci Rep 10:22203","DOI":"10.1038\/s41598-020-79198-x"},{"key":"836_CR48","doi-asserted-by":"crossref","unstructured":"Rieger K, De Filippi R, Lind\u00e9n O et al.\u00a090-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 years. (2022) Ann Hematol 101:781\u2013788","DOI":"10.1007\/s00277-022-04781-3"},{"key":"836_CR49","doi-asserted-by":"crossref","unstructured":"Saidi A, Stallons TA, Wong AG et al.\u00a0Side-by-Side Comparison of the In Vivo Performance of [212Pb]Pb-DOTAMTATE and Other SSTR2-Targeting Compounds. (2025) J Nucl Med 66:391\u2013397","DOI":"10.2967\/jnumed.124.268345"},{"key":"836_CR50","doi-asserted-by":"crossref","unstructured":"Sartor O, de Bono J, Chi KN et al.\u00a0Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. (2021) N Engl J Med 385:1091\u20131103","DOI":"10.1056\/NEJMoa2107322"},{"key":"836_CR51","doi-asserted-by":"crossref","unstructured":"Schuchardt C, Kulkarni HR, Prasad V et al.\u00a0The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE, (177)Lu-DOTANOC, and (177)Lu-DOTATOC. (2013) Recent Results Cancer Res 194:519\u2013536","DOI":"10.1007\/978-3-642-27994-2_30"},{"key":"836_CR52","doi-asserted-by":"crossref","unstructured":"Shirpour A, Hadadi A, Zolghadri S et al.\u00a0Preclinical evaluation of [13xLa]La-FAP-2286 as a novel theranostic agent for tumors expressing fibroblast activation protein. (2025) Sci Rep 15:7475","DOI":"10.1038\/s41598-025-91716-3"},{"key":"836_CR53","doi-asserted-by":"crossref","unstructured":"Taddio MF, Doshi S, Masri M et al.\u00a0Evaluating [225Ac]Ac-FAPI-46 for the treatment of soft-tissue sarcoma in mice. (2024) Eur J Nucl Med Mol Imaging 51:4026\u20134037","DOI":"10.1007\/s00259-024-06809-4"},{"key":"836_CR54","doi-asserted-by":"crossref","unstructured":"Umbricht CA, Bene\u0161ov\u00e1 M, Schmid RM et al.\u00a044Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617-preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617. (2017) EJNMMI Res 7:9","DOI":"10.1186\/s13550-017-0257-4"},{"key":"836_CR55","doi-asserted-by":"crossref","unstructured":"Umbricht CA, K\u00f6ster U, Bernhardt P et al.\u00a0Alpha-PET for Prostate Cancer: Preclinical investigation using 149Tb-PSMA-617. (2019) Sci Rep 9:17800","DOI":"10.1038\/s41598-019-54150-w"},{"key":"836_CR56","doi-asserted-by":"crossref","unstructured":"Walker LA.\u00a0Radioactive Yttrium 90: A Review of Its Properties, Biological Behavior, and Clinical Uses. (1964) Acta Radiol Ther Phys Biol 2:302\u2013314","DOI":"10.3109\/02841866409134063"},{"key":"836_CR57","doi-asserted-by":"crossref","unstructured":"Woods JJ, Rigby A, Wacker JN et al.\u00a0Synthesis and Evaluation of a Bifunctional Chelator for Thorium-227 Targeted Radiotherapy. (2025) J Med Chem 68:1682\u20131692","DOI":"10.1021\/acs.jmedchem.4c02423"},{"key":"836_CR58","doi-asserted-by":"crossref","unstructured":"Yang Y, Wang J, Zhong Y et al.\u00a0dvances in Radionuclide-Labeled Biological Carriers for Tumor Imaging and Treatment. (2025) ACS Appl Mater Interfaces 17:4316\u20134336","DOI":"10.1021\/acsami.4c19059"},{"key":"836_CR59","doi-asserted-by":"crossref","unstructured":"Zang J, Fan X, Wang H et al.\u00a0First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer. (2019) Eur J Nucl Med Mol Imaging 46:148\u2013158","DOI":"10.1007\/s00259-018-4096-y"},{"key":"836_CR60","doi-asserted-by":"crossref","unstructured":"Zhang J, Kulkarni HR, Baum RP.\u00a0Peptide Receptor Radionuclide Therapy Using 225Ac-DOTATOC Achieves Partial Remission in a Patient With Progressive Neuroendocrine Liver Metastases After Repeated \u03b2-Emitter Peptide Receptor Radionuclide Therapy.\u00a0(2020) Clin Nucl Med 45:241\u2013243","DOI":"10.1097\/RLU.0000000000002915"},{"key":"836_CR61","doi-asserted-by":"crossref","unstructured":"Zhang Y, Cai J, Hosmane NS, Zhu Y.\u00a0In silico assessments of the small molecular boron agents to pave the way for artificial intelligence-based boron neutron capture therapy. (2024) Eur J Med Chem 279:116841","DOI":"10.1016\/j.ejmech.2024.116841"},{"key":"836_CR62","doi-asserted-by":"crossref","unstructured":"Zhang Y, Coghi P, Ren Z, Hosmane NS, Zhu Y.\u00a0Comparison of Radionuclide Drug Conjugates With Boron Neutron Capture Therapy: An Overview of Targeted Charged Particle Radiation Therapy. (2025) Med Res Rev 45:867\u2013886","DOI":"10.1002\/med.22093"},{"key":"836_CR63","doi-asserted-by":"crossref","unstructured":"Zia NA, Cullinane C, Van Zuylekom JK et al.\u00a0A Bivalent Inhibitor of Prostate Specific Membrane Antigen Radiolabeled with Copper-64 with High Tumor Uptake and Retention. (2019) Angew Chem Int Ed 58:14991\u201314994","DOI":"10.1002\/anie.201908964"},{"key":"836_CR64","doi-asserted-by":"crossref","unstructured":"Zou Y, Que T, Sun P et al.\u00a0A novel PET tracer for noninvasive imaging the checkpoints expression of innate and adaptive immunity in tumors by simultaneously targeting CD24 and PD-L1. (2025) Bioorg Chem 157:108260","DOI":"10.1016\/j.bioorg.2025.108260"}],"container-title":["Handbook of Experimental Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2026_836","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:22:56Z","timestamp":1790349776000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/164_2026_836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":64,"URL":"https:\/\/doi.org\/10.1007\/164_2026_836","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"26 September 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}